Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $553.66 USD
Change Today +6.56 / 1.20%
Volume 501.1K
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (REGN) Key Developments

Sanofi and Regeneron Pharmaceuticals Announces Positive Phase III Results in Japanese Patients Treated with Praulent

Sanofi and Regeneron Pharmaceuticals announced results of a Phase III clinical study in Japanese patients treated with the investigational therapy Praluent (alirocumab), targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). The Phase III trial (ODYSSEY JAPAN) met its primary endpoint - demonstrating low-density lipoprotein cholesterol (LDL-C) - in Japanese patients with hypercholesterolaemia at high cardiovascular risk and/or with high-cholesterol owing to the medical condition heterozygous familial hypercholesterolaemia (HeFH). The 24-week trial involved 216 Japanese patients treated with Praulent alongside statins. Patient groups were administered with a dose of 75 mg initially. That dose was increased to 150 mg for two patients who failed to reach their LDL-C target by week 8. The mean LDL-C value at baseline was 141.2 mg/dL. Praluent demonstrated significant cholesterol-lowering ability with patients showing an average 64% reduction in LDL-C.

Regeneron Pharmaceuticals Wins Japanese Approval for EYLEA (Aflibercept) Injection for Treating Retinal Vein Occlusion

Regeneron Pharmaceuticals reported that they won approval for EYLEA (aflibercept) Injection in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO), a significant cause of vision impairment and a chronic disease that requires early and ongoing management to obtain the best possible vision. This approval was awarded to Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin Ltd, by the Ministry of Health, Labour and Welfare (MHLW). This Japanese approval is based on positive results from the company's double-masked, randomized, active-controlled phase 3 VIBRANT study in patients with visual impairment due to macular edema secondary to BRVO. The company stated the primary endpoint was the proportion of subjects who gained at least 15 letters in best corrected visual acuity (BCVA) from baseline at week 24, as measured on the Early Treatment Diabetic Retinopathy Scale (ETDRS) eye chart, a standard chart used in research to measure visual acuity.

Regeneron Pharmaceuticals, Inc. Approves Amendment to Certificate of Incorporation

Regeneron Pharmaceuticals, Inc. announced that at the annual meeting of shareholders held on June 12, 2015 approved an amendment to the company's certificate of incorporation to increase the number of authorized shares of capital stock and common stock.

Regeneron Pharmaceuticals Inc. Announces FDA Approval of Sanofi and Regeneron's Praluent(R) (Alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to three (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.

Regeneron Pharmaceuticals Inc. Announces Updates on Phase 3 Study of Sarilumab

Regeneron Pharmaceuticals Inc. announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo. The study, called SARIL-RA-TARGET, evaluated the efficacy and safety of two subcutaneous sarilumab doses versus placebo, added to non-biologic disease modifying anti-rheumatic drugs (DMARD) therapy in RA patients who were inadequate responders to or intolerant of TNF-alpha inhibitors (TNF-IR). The SARIL-RA-TARGET trial enrolled 546 TNF-IR patients who were randomized to one of three treatment groups self-administered subcutaneously (SC) every other week (Q2W): sarilumab 200 milligrams (mg), sarilumab 150 mg, or placebo, in addition to DMARD therapy. Both sarilumab groups showed clinically relevant and statistically significant improvements compared to the placebo group in both co-primary endpoints (p greater than 0.001): Improvement in signs and symptoms of RA at 24 weeks, as measured by the American College of Rheumatology score of 20% improvement (ACR20), were as follows: 61% in the sarilumab 200 mg group; 56% in the sarilumab 150 mg group; and 34% in the placebo group, all in combination with DMARD therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $553.66 USD +6.56

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $146.27 USD +1.71
Incyte Corp $104.28 USD +1.32
Kyowa Hakko Kirin Co Ltd ¥2,018 JPY +39.00
UCB SA €70.46 EUR +3.46
Vertex Pharmaceuticals Inc $135.00 USD -0.46
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 100.0x
Price/Sales 18.5x
Price/Book 19.0x
Price/Cash Flow 160.7x
TEV/Sales 18.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.